Healthcare / Diagnostics & ResearchMCE
$1.58
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$57M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.9%
↓Gross Margin
99.3%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+49.3%
FCF CAGR
—
FCF margin
-20.6%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.5M · net income $-3.6M · FCF $-3.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.5M | $14.5M | $14.3M | $7.4M | $4.4M |
| Net Income | $-3.6M | $-3.6M | $-1.2M | $-4.5M | $-2.7M |
| EBITDA | $-945655.00 | $-945655.00 | $1.2M | $-514747.00 | $-1.4M |
| EPS | — | — | -0.03 | -0.15 | -0.09 |
| Gross Margin | 99.3% | 99.3% | 100.1% | 101.0% | 94.1% |
| Operating Margin | -25.1% | -25.1% | -14.0% | -32.6% | -50.3% |
| Net Margin | -24.8% | -24.8% | -8.2% | -61.0% | -62.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.25 | 0.30 | 0.16 |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.0M | $-3.0M | $-5.1M | $-2.7M | $-3.7M |
| Returns | |||||
| ROE | -16.9% | -16.9% | -5.3% | -25.1% | -11.8% |
| Valuation | |||||
| EV/EBITDA | — | — | 52.58 | — | — |
| P/B | 2.66 | 2.66 | 2.72 | 2.47 | 1.96 |
| Growth & Yield | |||||
| Revenue Growth | 1.8% | 1.8% | 93.1% | 69.2% | — |
| EPS Growth | — | — | 77.1% | -67.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
-7.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.